摘要
目的:对比分析c-erbB-2基因(HER2)阳性乳腺癌患者TCbHP新辅助化疗方案中使用卡铂和洛铂的疗效及安全性。方法:回顾性分析2020年4月—2021年4月于南京鼓楼医院乳腺外科行TCbHP新辅助化疗的76例女性HER2阳性乳腺癌患者的临床资料,其中使用卡铂(CBP)治疗的46例为CBP组,使用洛铂(LBP)治疗的30例为LBP组,两组均接受6个周期(21 d/周期)的新辅助化疗。对比观察两组病理完全缓解(PCR)率、血清肿瘤标志物水平及不良反应情况。结果:(1)LBP组的PCR率为90.0%,较CBP组的65.2%高(P<0.05)。(2)治疗后,LBP组的糖蛋白抗原153(CA153)、糖蛋白抗原125(CA125)及组织多肽特异性抗原(TPS)水平均较CBP组低(P<0.05)。(3)CBP组白细胞减少和中性粒细胞减少的发生率分别为80.43%、47.83%,LBP组分别为36.67%、33.33%;CBP组血小板减少和血红蛋白下降发生率为67.39%、89.13%,LBP组为10.00%、66.67%,上述指标差异均有统计学意义(P<0.05);两组均出现AST升高,但比较差异无统计学意义(P>0.05)。(4)两组不良反应情况比较差异无统计学意义(P>0.05)。结论:HER2阳性乳腺癌患者TCbHP新辅助化疗方案应用LBP的疗效较CBP更佳,安全性更高,可提高PCR率,减轻骨髓抑制反应。
Objective: To compare and analyze the efficacy and safety of Carboplatin and Lobaplatin in TCbHP neoadjuvant chemotherapy for patients with c-erbB-2 gene(HER2) positive breast cancer. Method: The clinical data of 76 female HER2 positive breast cancer patients who underwent TCbHP neoadjuvant chemotherapy in the Breast Surgery Department of Nanjing Drum Tower Hospital from April 2020 to April 2021 were analyzed retrospectively. Among them, 46 patients treated with Carboplatin(CBP) were CBP group, and the 30 patients treated with Lobaplatin(LBP) were LBP group. Both groups received neoadjuvant chemotherapy for 6 cycles(21 d/cycle). The pathological complete remission(PCR) rate, serum tumor markers and adverse reactions were observed and compared between the two groups. Result:(1) The PCR rate in LBP group was 90.0%, which was higher than 65.2% in CBP group(P<0.05).(2) After treatment, the levels of glycoprotein antigen 153(CA153), glycoprotein antigen 125(CA125) and tissue polypeptide specific antigen(TPS) in LBP group were lower than those in CBP group(P<0.05).(3) The incidence of leucopenia and neutropenia in CBP group were 80.43% and 47.83% respectively, and those in LBP group were 36.67% and 33.33% respectively, the incidence of thrombocytopenia and hemoglobin decrease in CBP group was 67.39% and 89.13%, while those in LBP group were 10.00% and 66.67%, the differences of the above indexes between the two groups were statistically significant(P<0.05). AST increased in both groups, but there was no significant difference(P>0.05).(4) There was no significant difference in adverse reactions between the two groups(P>0.05). Conclusion: LBP is more effective and safe than CBP in TCbHP neoadjuvant chemotherapy for patients with HER2 positive breast cancer, which can improve the pathological complete remission rate and reduce bone marrow suppression reaction.
作者
尹羲
施佳君
叶佳慧
吴宝娟
张伟杰
YIN Xi;SHI Jiajun;YE Jiahui;WU Baojuan;ZHANG Weijie(Nanjing Drum Tower Hospital,Nanjing 210009,China;不详)
出处
《中外医学研究》
2023年第5期107-111,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
HER2阳性
乳腺癌
新辅助化疗
TCbHP化疗方案
洛铂
卡铂
病理完全缓解
HER2 positive
Breast cancer
Neoadjuvant chemotherapy
TCbHP chemotherapy regimen
Lobaplatin
Carboplatin
Pathological complete remission
